Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort.

Vibeke StrandeCharlotte LundMilada HagenMay-Bente BengtsonRaziye Boyar CetinkayaTrond Espen DetlieSvein Oskar FrigstadOle HøieAsle W MedhusMagne HenriksenKristina I Aass HoltenØistein HovdeGert Huppertz-HaussIngunn JohansenBjørn Christian OlsenRandi OpheimPetr RicanekRoald TorpTor TønnessenSimen VatnTone Bergene AabrekkMarte Lie HøivikVendel A Kristensen

Published in: Alimentary pharmacology & therapeutics (2024)

In this population-based inception cohort, colectomy rate in the first year after diagnosis was low, and a high proportion of patients were in remission at 1-year follow-up. The use of biologic therapy increases, consistent with findings from previous studies.

Keyphrases

ulcerative colitis
end stage renal disease
newly diagnosed
ejection fraction
rheumatoid arthritis
prognostic factors
peritoneal dialysis
stem cells
patient reported outcomes
disease activity